Smith & Nephew takes “repless” pilot program into Australia, New Zealand and Europe

January 13, 2015 by Brian Johnson

Smith & Nephew says its ‘no-frills’ Syncera program, which replaces sales reps with an automated system, has performed so well that the company will expand it into Australia, New Zealand and the European Union.

Smith & Nephew (FTSE:SN, NYSE:SNN) plans to expand its Syncera pilot program, which replaces OR sales reps with an automated system, into 3 more markets, CEO Olivier Bohoun told investors yesterday.

Syncera, a “no frills” program for the British medical device company’s orthopedics business, aims to cut implant prices in half by removing sales representatives from the operating room and replacing them with an automated technology solution.

Smith & Nephew launched Syncera last summer in the U.S. as part of a pilot program aimed at cutting hip and knee replacement device prices by 40% to 50%. At the time, company officials estimated the target market for Syncera at 5% to 10% of U.S. hospitals.


Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

One Comment

  1. Interesting but not surprised with US international sales programs using international distributors for several benefits some f them being: lower over head. close relationships that present high service quality & lower malpractice legality insurance.

Back to top button